| Abstract: |
Symptoms of drug-associated interstitial lung disease (ILD) are nonspecific and can be difficult to distinguish from a number of illnesses that commonly occur in patients with non-small-cell lung cancer (NSCLC) on therapy. Identification of drug involvement and differentiation from other illnesses is problematic, although radiological manifestations and clinical tests enable many of the alternative causes of symptoms in advanced NSCLC to be excluded. In lung cancer patients, high-resolution computed tomography (HRCT) is more sensitive than a chest radiograph in evaluating the severity and progression of parenchymal lung disease. Indeed, the use of HRCT imaging has led to the recognition of many distinct patterns of lung involvement and, along with clinical signs and symptoms, helps to predict both outcome and response to treatment. This manuscript outlines the radiology of drug-associated ILD and its differential diagnosis in NSCLC. An algorithm that uses clinical tests to exclude alternative diagnoses is also described. © 2004 Cancer Research UK. |
| Keywords: |
treatment outcome; prednisone; disease course; review; gemcitabine; paclitaxel; diagnostic procedure; diagnosis, differential; lung disease; lung non small cell cancer; antineoplastic combined chemotherapy protocols; carcinoma, non-small-cell lung; lung neoplasms; differential diagnosis; tomography, x-ray computed; algorithms; docetaxel; radiography, thoracic; disease severity; algorithm; evaluation; disease progression; gefitinib; bleomycin; interstitial lung disease; methylprednisolone; thorax radiography; azathioprine; symptomatology; corticosteroid; mitomycin; radiodiagnosis; drug induced disease; antihistaminic agent; lung parenchyma; histamine h2 receptor antagonist; high resolution computer tomography; lung diseases, interstitial; humans; human; priority journal; drug-associated ild; lung cancer nsclc
|
